Tebbutt N C, Norman A R, Cunningham D, Hill M E, Tait D, Oates J, Livingston S, Andreyev J
Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK.
Gut. 2003 Apr;52(4):568-73. doi: 10.1136/gut.52.4.568.
The role of palliative resection of the primary tumour in patients who present with metastatic colorectal cancer is unclear.
This study compared the incidence of major intestinal complications in such patients who received chemotherapy treatment with or without prior palliative resection of the primary tumour.
The incidence of intestinal obstruction, perforation, fistula formation, and gastrointestinal haemorrhage, and the requirement for abdominal radiotherapy in patients with metastatic colorectal cancer treated at a single institution over a 10 year period was determined.
Eighty two patients received initial treatment with chemotherapy without resection of the primary tumour (unresected group) and 280 patients had undergone prior resection (resected group). In the unresected group, the incidence of peritonitis, fistula formation, and intestinal haemorrhage was 2.4% (95% confidence interval (CI) 0.3-8.5%), 3.7% (95% CI 0.8-10.3%), and 3.7% (95% CI 0.8-10.3%), respectively, and was not significantly different from the resected group. Intestinal obstruction affected 13.4% (95% CI 6.9-22.7%) of patients in the unresected group and 13.2% (95% CI 9.2-17.2%) of patients in the resected group. More patients in the unresected group required >/=3 blood transfusions (14.6% v 7.5%; p=0.048) and abdominal radiotherapy (18.3% v 9.6%; p=0.03) than the resected group.
The incidence of major intestinal complications in patients with unresected colorectal cancer and synchronous metastases who receive initial treatment with chemotherapy is low. Chemotherapy may be successfully used as initial treatment for such patients with no increased risk of most major intestinal complications compared with patients who have undergone initial resection of the primary tumour.
对于出现转移性结直肠癌的患者,原发肿瘤姑息性切除的作用尚不清楚。
本研究比较了接受化疗治疗的此类患者在有无原发肿瘤姑息性切除的情况下,严重肠道并发症的发生率。
确定了在一家机构接受治疗的转移性结直肠癌患者在10年期间肠梗阻、穿孔、瘘管形成和胃肠道出血的发生率,以及腹部放疗的需求。
82例患者接受了初始化疗且未切除原发肿瘤(未切除组),280例患者曾接受过切除(切除组)。在未切除组中,腹膜炎、瘘管形成和肠道出血的发生率分别为2.4%(95%置信区间(CI)0.3 - 8.5%)、3.7%(95%CI 0.8 - 10.3%)和3.7%(95%CI 0.8 - 10.3%),与切除组无显著差异。肠梗阻影响未切除组13.4%(95%CI 6.9 - 22.7%)的患者和切除组13.2%(95%CI 9.2 - 17.2%)的患者。未切除组中需要≥3次输血(14.6%对7.5%;p = 0.048)和腹部放疗(18.3%对9.6%;p = 0.03)的患者比切除组更多。
未切除的结直肠癌并伴有同步转移且接受初始化疗治疗的患者,严重肠道并发症的发生率较低。与接受过原发肿瘤初始切除的患者相比,化疗可成功用作此类患者的初始治疗,且大多数严重肠道并发症的风险不会增加。